perphenazine has been researched along with Chemical Dependence in 9 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
Excerpt | Relevance | Reference |
---|---|---|
"Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment." | 5.13 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008) |
"Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone." | 2.58 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (33.33) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Temmingh, HS | 1 |
Williams, T | 1 |
Siegfried, N | 1 |
Stein, DJ | 1 |
Mohamed, S | 1 |
Rosenheck, RA | 1 |
Lin, H | 1 |
Swartz, M | 1 |
McEvoy, J | 1 |
Stroup, S | 1 |
FRANKAU, L | 1 |
Swartz, MS | 1 |
Wagner, HR | 1 |
Swanson, JW | 1 |
Stroup, TS | 1 |
McEvoy, JP | 1 |
Reimherr, F | 1 |
Miller, DD | 1 |
McGee, M | 1 |
Khan, A | 1 |
Canive, JM | 1 |
Davis, SM | 1 |
Hsiao, JK | 1 |
Lieberman, JA | 1 |
Ghoreishi, A | 1 |
Goodhue, A | 1 |
Bartel, RL | 1 |
Smith, NB | 1 |
Bowers, MB | 1 |
Mazure, CM | 1 |
Nelson, JC | 1 |
Jatlow, PI | 1 |
de la Garza, R | 1 |
Johanson, CE | 1 |
Dorfman, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
Intervention | Units on a scale (Mean) |
---|---|
QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
Intervention | Drinking Days per Week (Mean) |
---|---|
QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
Intervention | drinking days per week (Number) |
---|---|
Risperidone Long Acting Injectable (LAI) | 2.84 |
Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
Intervention | ordinal severity of impairment (Number) |
---|---|
Risperidone Long Acting Injectable (LAI) | 50.8 |
Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
Intervention | ordinal severity of symptoms (Number) |
---|---|
Risperidone Long Acting Injectable (LAI) | 78.2 |
Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
Intervention | ordinal unit of severity (Number) |
---|---|
Risperidone Long Acting Injectable (LAI) | 4.02 |
Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
Intervention | heavy drinking days per week (Number) |
---|---|
Risperidone Long Acting Injectable (LAI) | -.11 |
Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
Intervention | Participants (Count of Participants) |
---|---|
Risperidone Long Acting Injectable (LAI) | 43 |
Oral Risperidone Aka Risperdal | 28 |
1 review available for perphenazine and Chemical Dependence
Article | Year |
---|---|
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor | 2018 |
2 trials available for perphenazine and Chemical Dependence
Article | Year |
---|---|
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub | 2008 |
6 other studies available for perphenazine and Chemical Dependence
Article | Year |
---|---|
TREATMENT IN ENGLAND OF CANADIAN PATIENTS ADDICTED TO NARCOTIC DRUGS.
Topics: Antisocial Personality Disorder; Ascorbic Acid; Canada; England; Folic Acid; Heroin; Humans; London; | 1964 |
A somatic type delusional disorder secondary to peripheral neuropathy: a case report.
Topics: Adult; Amitriptyline; Biperiden; Brachial Plexus; Delusions; Drug Overdose; Drug Therapy, Combinatio | 2008 |
Exacerbation of psychosis by phenylpropanolamine.
Topics: Adult; Female; Hallucinations; Humans; Methamphetamine; Nasal Decongestants; Paranoid Disorders; Par | 2000 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
The effects of food deprivation on the self-administration of psychoactive drugs.
Topics: Animals; Cocaine; Dextroamphetamine; Diazepam; Food Deprivation; Macaca mulatta; Male; Nicotine; Per | 1987 |
Combined use of an anti-depressant with tranquilizer in the management of depression.
Topics: Amitriptyline; Anxiety; Bipolar Disorder; Depression; Drug Synergism; Electroconvulsive Therapy; Hum | 1966 |